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1. Introduction
Bovine respiratory syncytial virus (BRSV) is a primary 
cause of lower respiratory tract disease in calves and is 
an etiological component of the bovine respiratory dis-
ease complex [1]. BRSV is a member of the genus Pneu-
movirus in the family Paramyxoviridae [2]. Infection with 
BRSV following vaccination, or re-infection following 
natural infection is common since protection is incom-
plete [3]. The attachment (G) and fusion (F) surface glyco-
proteins are the most immunogenic in humoral immunity 
[4]. Monoclonal antibodies to the G or F protein protect 
against lower respiratory tract infection [4]. Priming of 
mice with the F protein elicits protective cytotoxic T lym-
phocyte (CTL) and T-helper (TH) cell responses [5].
The BRSV F glycoprotein is a type I envelope glyco-
protein which plays an important role in fusion of the 
viral envelope to the host cell membrane. The F protein 
causes infected cells to fuse to adjacent cells, forming syn-
cytia, or multi-nucleated cells [6]. The F protein is synthe-
sized as an inactive precursor, F0, which is then cleaved 
to form two disulfide-linked subunits, F1 and F2 [7]. The F 
protein is post-translationally modified by cleavage, fold-
ing and glycosylation before being transported to the cell 
surface [8]. Depending on the BRSV strain, the F protein 
may have either three or four N-glycosylation sites. Two 
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Abstract
Bovine respiratory syncytial virus (BRSV) is an etiological component of the bovine respiratory tract disease complex. Infection 
with BRSV following vaccination, or re-infection following natural infection is common since protection is incomplete. The ob-
jectives of this study were to create plasmid DNA constructs encoding single or multiple N-glycosylation-site deletion BRSV fu-
sion (F) proteins, and evaluate their expression in cell culture, and potential to induce anti-BRSV F antibody responses in BALB/
c mice. Four plasmid DNAs were constructed, each encoding 1-4 N-glycosylation-site deletions: Gly4, Gly2/4, Gly1/2/4 and 
Gly1/2/3/4. Each of the N-glycosylation-site deletion BRSV F proteins were expressed in COS-7 cells following transfection with 
plasmid DNA. Inoculation of BALB/c mice with plasmid DNA, resulted in a significant anti-BRSV F IgG response to the wild-
type (WT) F and glycosylation-site deletion protein Gly2/4. Gly2/4 elicited a higher antibody titer than the fully glycosylated WT 
F protein. Significant neutralizing antibody titers were detected following immunization with the Gly2/4 plasmid DNA. These 
glycosylation-site deletion BRSV F proteins will be useful to characterize the effects of glycosylation on immunogenicity in the 
natural host, and may lead to a new approach for the generation of BRSV vaccines.
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or three sites are located on the F2 subunit, while one site 
is located on the F1 subunit [9, 10]. Glycosylation is an im-
portant modification that can affect the folding, transport, 
and immunogenicity of proteins [11].
Carbohydrate moieties on surface glycoproteins, such 
as the F protein, may modulate immunogenicity of the 
protein. Glycans can shield large regions of the protein 
surface, providing protection from proteases and mask-
ing epitopes. It is also possible that the removal of carbo-
hydrates cause a shift in the conformation of the polypep-
tide backbone, altering the recognition of immunogenic 
epitopes [12]. Palomo et al. [13], showed that removal of 
carbohydrates on the G protein of human respiratory syn-
cytial virus (HRSV) reduced recognition by monoclonal 
antibodies (MAbs). Of the 18 MAbs that originally recog-
nized the fully O- and N-glycosylated protein, only five 
MAbs recognized the unglycosylated G protein. In this 
case, the carbohydrates comprised the epitope, or were 
necessary for recognition of the epitope by the MAbs [13].
Completely effective vaccines for both HRSV and 
BRSV are yet to be developed. Previously, a formalin-in-
activated (FI) HRSV vaccine was used which exacerbated 
illness in vaccinated children following natural exposure 
to the virus [14]. Vaccine-enhanced respiratory disease 
has also been reported in calves using an experimental FI-
BRSV vaccine [15]. A number of approaches have been ex-
plored to develop a more effective vaccine. One approach 
has been the development of DNA vaccines, which have 
advantages over the live- or FI-vaccines. DNA vaccines 
are safer, more cost-effective and can be manipulated to 
alter the qualitative and quantitative humoral and cellu-
lar immune responses [16].
Plasmid DNA vaccines encoding the G and F proteins 
of HRSV have been effective in inducing neutralizing an-
tibodies. Intramuscular inoculation with plasmid DNA 
encoding the F glycoprotein resulted in high neutraliz-
ing antibody titers, protection against live challenge and 
production of interferon-γ and CD8+ CTLs [17]. The im-
munization of mice with plasmid DNA encoding the full-
length and secreted HRSV G resulted in a balanced Th1/
Th2 response following virus challenge [17]. The objec-
tives of this study were to create plasmid DNA constructs 
encoding WT and N-linked glycosylation-site deletion 
BRSV F proteins and to characterize expression in cell 
culture and induction of antibody responses in BALB/c 
mice.
2. Materials and methods
2.1. Cells and viruses
Bovine turbinate (BT) cells (National Veterinary Ser-
vices Laboratory, Ames, IA) and African green monkey 
kidney (COS-7) cells (American Type Culture Collec-
tion, CRL-1651, Rockville, MD) were grown in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 
10% equine serum (Hyclone, Logan, UT) and maintained 
in a 37 °C humidified chamber with 5% CO2. Confluent 
monolayers were infected with BRSV strain 375 at a mul-
tiplicity of infection (m.o.i.) of 0.01 in tissue culture flasks. 
Inoculated cell cultures were maintained at 33 °C in a hu-
midified chamber with 5% CO2 (~2 weeks) until the cells 
developed 50% cytopathic effect (CPE). Cells were frozen 
at −80 °C, thawed, dispensed into aliquots, then frozen 
again at −80 °C until used. Recombinant vaccinia virus 
expressing T7 polymerase (vvT7) was kindly provided by 
Dr. Bernard Moss (National Institute of Health, Bethesda, 
MD).
2.2. Construction of plasmid DNA vector encoding the wild-
type BRSV F glycoprotein
Viral RNA was isolated from BRSV-infected BT cells 
using TRIZOL LS reagent (Invitrogen, Carlsbad, CA) ac-
cording to the manufacturer’s instructions. The 1800 bp 
BRSV F glycoprotein cDNA sequence was generated from 
total RNA using Superscript II reverse transcriptase (Invi-
trogen) and the primer F2, 5′-GGATCCAAAAATGCAG-
GTCTTGGCGGATAC-3′, complementary to nucleotide 
base numbers 1801–1824 of the BRSV 375 F glycoprotein, 
with a BamHI restriction site incorporated (underlined). 
The BRSV F cDNA was amplified using Taq polymerase 
(Invitrogen), with primers F2 and F1, 5′-GGATCCATA-
AGGATGGCGGCAACAGC-3′, corresponding to nucleo-
tide base numbers 1–14 of BRSV F. The BRSV F specific 
primers were purchased from Sigma Genosys (Wood-
lands, TX). The reaction mixture was denatured at 94 °C 
for 1 min, annealed at 50 °C for 1 min and extended at 
72 °C for 2 min for a total of 30 cycles, followed by an ad-
ditional extension of 7 min at 72 °C.
The BRSV F PCR product was gel purified (QIAEX 
II Gel Extraction Kit, QIAGEN, Valencia, CA) and sub-
cloned into the pCR 2.1 vector using the TA Cloning Kit 
(Invitrogen). The BRSV F cDNA was excised from the 
pCR 2.1 vector using restriction enzymes SpeI and NotI, 
and ligated using T4 DNA ligase into the mammalian ex-
pression vector, pcDNA 3.1/His (Invitrogen), previously 
digested with NotI and XbaI, creating the construct 3.1/
His/F. This placed the BRSV F cDNA downstream of the 
T7 RNA polymerase and upstream of the bovine growth 
hormone polyadenylation signal sequence. DNA se-
quencing (DNA Sequencing Facility, Iowa State Univer-
sity, Ames, IA) was performed after cloning to confirm 
the insert was in the proper reading frame.
2.3. Construction of N-glycosylation-site deletion BRSV F 
proteins
The N-glycosylation deletion BRSV F protein coding 
regions were generated by replacing the asparagine trip-
let (AAC) at positions N27, N70, N120 and N500 of the 
3.1/His/F cDNA with the alanine triplet (GCC) using the 
QuikChange Site-Directed Mutagenesis Kit (Stratagene, 
La Jolla, CA) according to the manufacturer’s instructions. 
Site-directed mutagenesis was performed using Pfu-
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Turbo™ DNA polymerase, and glycosylation-site specific 
primers (Figure 1). BRSV F N-glycosylation-site specific 
primers containing the two nucleotide changes were pur-
chased from Sigma Genosys (Woodlands, TX). The reac-
tion mixture was denatured at 95 °C for 30 s, annealed at 
55 °C for 1 min and extended at 68 °C for 14 min, for a to-
tal of 16 cycles. Following temperature cycling, the prod-
uct was treated with DpnI endonuclease at 37 °C for 1 h to 
digest the parental DNA. The PCR-synthesized plasmid 
DNA was then transformed into XL-1 Blue Supercompe-
tent Cells (Stratagene). Ampicillin-resistant colonies were 
selected and plasmid DNA extracted using the Wizard 
Plus Mini-Prep Kit (Promega) according to the manufac-
turer’s instructions. The nucleotide exchanges were con-
firmed by DNA sequencing. Plasmid DNA encoding the 
glycosylation-site deletion proteins was identified accord-
ing to the deleted glycosylation-site(s) (i.e. Gly2/4 had the 
second and fourth N-glycosylation-sites deleted).
2.4. Expression of BRSV F N-glycosylation-site deletion pro-
teins in mammalian cells
Expression of the WT and N-glycosylation-site dele-
tion BRSV F proteins was evaluated in COS-7 cells fol-
lowing transfection using a vaccinia virus-T7 RNA poly-
merase expression system [18]. Following infection with 
T7-vaccinia virus, COS-7 cells were transfected with plas-
mid DNA using a cationic lipid-mediated method (Lipo-
fectAMINE 2000 Reagent, Invitrogen) according to the 
manufacturer’s instructions.
Twenty-four hours following transfection, the COS-
7 cells were fixed with 20% acetone (v/v) in phosphate-
buffered saline (PBS). The BRSV F protein was detected 
using an immunoperoxidase staining protocol [19] with 
MAb 8G12, specific for BRSV F, as the primary antibody 
and biotinylated horse anti-mouse IgG (H + L) (Vector 
Laboratories, Burlingame, CA) as the secondary antibody. 
Antibody binding was detected using streptavidin horse-
radish peroxidase conjugate (Zymed, San Francisco, CA) 
and 3-amino-9-ethyl-carbazole substrate (AEC, Sigma, St. 
Louis, MO). Additionally, cells were transfected and lysed 
with 0.5% NP-40 lysis buffer, then proteins separated by 
discontinuous SDS-PAGE electrophoresis. The separated 
proteins were transferred onto a nitrocellulose membrane 
and non-specific sites blocked by incubation with PBS, pH 
7.6, containing 5% nonfat dry milk. The membrane was 
then incubated with the primary antibody, MAb 8G12 
(1:1000), followed by alkaline phosphatase-labeled goat 
anti-mouse IgG (H + L) (KPL, Gaithersburg, MD) as the 
secondary antibody. Antibody binding was detected us-
ing 5-bromo-4-chloro-3-indolylphosphate/nitroblue tet-
razolium substrate (KPL, Gaithersburg, MD).
2.5. DNA inoculation of BALB/c mice
Prior to initiation of the experiments, this project was 
reviewed and approved by the University of Nebraska In-
stitutional Animal Care and Use Committee to ensure hu-
mane use and treatment of animals, and guidelines were 
adhered to throughout the course of the study. Plasmid 
Figure 1. Glycosylation-site specific primers used to make BRSV F N-glycosylation-site deletion proteins for DNA inoculation of 
BALB/c mice. The double nucleotide change is underlined. The first two nucleotides of the triplet codons were changed to ex-
change the asparagine triplet codon (AAC) with an alanine triplet codon (GCC) to create plasmid DNA encoding N-glycosylation-
site deletion proteins: Gly4, Gly2/4, Gly1/2/4 and Gly1/2/3/4.
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DNA encoding the WT F and the N-glycosylation-site 
deletion proteins was purified using a plasmid Mega kit 
from QIAGEN according to the manufacturer’s instruc-
tions. The purified DNA pellet was resuspended in 0.89% 
NaCl. Seven-week-old female, specific pathogen-free 
BALB/c mice, purchased from Charles River Laboratories 
(Wilmington, MA), were housed in BL-2 rooms at the An-
imal Research Facility, University of Nebraska-Lincoln.
The mice were assigned to one of seven treatment 
groups: (1) pcDNA 3.1/His encoding the fully glycosyl-
ated BRSV F protein (WT F), (2) pcDNA 3.1/His encod-
ing a single glycosylation-site deletion protein (Gly4), (3) 
pcDNA 3.1/His encoding a double glycosylation-site de-
letion protein (Gly2/4), (4) pcDNA 3.1/His encoding a 
triple glycosylation-site deletion protein (Gly1/2/4), (5) 
pcDNA 3.1/His encoding a quadruple glycosylation-site 
deletion protein (Gly1/2/3/4), (6) live BRSV virus, or (7) 
no treatment. Each treatment group was comprised of 
four or five mice. Mice were inoculated in the rectus fem-
oris muscle with 100 μg of plasmid DNA. Booster inocula-
tions were given at 4 and 8 weeks, by the same route and 
with the same dose of plasmid DNA. Three weeks fol-
lowing the final inoculation (day 78), all mice were anes-
thetized by injecting intramuscularly (IM) with 40 μg/g 
ketamine and 6 μg/g Xylazine and bled by cardiac punc-
ture. An equal amount of Alsever’s solution was added 
to the blood. The mice were then euthanatized by CO2 
inhalation.
2.6. Antibody responses in mice following plasmid DNA 
inoculation
Plasma was analyzed for anti-BRSV F antibodies using 
an indirect enzyme-linked immunosorbent assay (ELISA), 
with modifications [20]. BT cells infected with BRSV us-
ing an m.o.i. of 0.1 were used as antigen and propagated 
in 96-well microtiter plates. Following incubation for 4 
days, cells were fixed with 20% acetone in PBS (v/v). In-
fected cells were blocked with 1% bovine serum albumin 
(BSA) in PBS with 0.15% Tween for 1 h at 37 °C. Two-fold 
dilutions (1:10–1:1280) of mouse plasma were prepared, 
added to the cells and incubated for 1 h at 37 °C. Cells 
were then incubated with alkaline phosphatase-labeled 
goat anti-mouse IgG (H + L) (KPL, Gaithersburg, MD), 
diluted 1:1000 in 0.1% BSA in PBS-Tween, for 1 h at 37 °C. 
The substrate, p-nitrophenyl phosphate, was then added, 
incubated at room temperature for 30 min and the optical 
density (OD) values were determined using a microplate 
reader (MR 700, Dynatech Laboratories) at 410 nm.
Neutralizing antibody titers were determined by com-
bining serial two-fold dilutions (1:2–1:256) of heat-inacti-
vated (56 °C for 30 min) plasma with BRSV (150 TCID50/
50 μl) in 96-well microtiter plates for 1 h at 37 °C with 5% 
CO2. Following incubation, 1 × 105 BT cells were added to 
each well and incubated 5 days at 37 °C. Cells were ex-
amined microscopically for viral CPE and then fixed with 
20% acetone in PBS (v/v). Plates were stained with an im-
munoperoxidase staining assay [19] and virus neutraliz-
ing antibody titers were determined as the highest plasma 
dilution inhibiting BRSV CPE.
2.7. Statistical analysis
Results in the different treatment groups of mice for 
both the ELISA and neutralization assays were com-
pared and analyzed statistically using analysis of vari-
ance [21]. ELISA antibody and virus neutralizing anti-
body titers for each treatment group were compared to 
all other treatment groups to identify difference between 
treatments. P values of <0.05 were considered to be statis-
tically significant.
3. Results
3.1. Plasmid DNA vectors encoding BRSV F N-glycosylation-
site deletion proteins
The plasmids encoding the WT and each of the four 
BRSV F N-glycosylation deletion proteins for DNA inocu-
lation were constructed and DNA sequencing confirmed 
that the specific asparagine triplet(s) were replaced with 
alanine triplet(s) for each of the glycosylation-site dele-
tion plasmids, as well as in the proper reading frame. The 
vectors encoded: (1) WT BRSV F protein; (2) BRSV F Gly4 
protein (deletion of N500); (3) BRSV F Gly2/4 protein (de-
letion of N70 and N500); (4) BRSV F Gly1/2/4 protein (de-
letion of N27, N70 and N500) or (5) BRSV F Gly1/2/3/4 
protein (deletion of N27, N70, N120 and N500) (Figure 2). 
Using a T7-vaccinia virus expression system, transcrip-
tion was under control of the T7 promoter.
3.2. COS-7 cells express the BRSV F N-glycosylation-site 
deletion proteins
Expression of the F proteins was evaluated using an im-
munoperoxidase assay. Cytoplasmic staining was detected 
in the COS-7 cells transfected with each of the plasmid 
Figure 2. Schematic drawing of the plasmid DNAs encoding 
the wild-type (WT) and N-glycosylation-site deletion BRSV F 
proteins Gly4, Gly2/4, Gly1/2/4, and Gly1/2/3/4 constructed 
using site-directed mutagenesis. Arrows illustrate the loca-
tion of the N-glycans. The fully glycosylated WT F has N-gly-
cans located at asparagine residues 27, 70, 120 and 500. Each 
plasmid DNA encoding a different glycosylation-site deletion 
protein was named according to the specific N-glycan site(s) 
deleted.
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DNAs encoding the N-glycosylation-site deletion BRSV F 
proteins (Figure 3). The staining intensity of cells trans-
fected with each plasmid DNA construct was comparable 
to staining of cells transfected with the WT F. No staining 
was observed in the negative control, COS-7 cells trans-
fected with the plasmid pcDNA 3.1 backbone.
Cell lysates were collected from COS-7 cells trans-
fected with plasmid DNA encoding the BRSV F WT and 
N-glycosylation-site deletion proteins. Western blot anal-
yses showed that each N-glycosylation-site deletion pro-
tein and the WT F protein resolved as a 68 kDa band, with 
the F1 subunit resolving as a faint 48 kDa band (data not 
shown).
3.3. BRSV F antibody response of BALB/c mice following plas-
mid DNA inoculation
To evaluate the IgG antibody response, plasma sam-
ples from mice immunized with plasmid DNA encoding 
the BRSV F N-glycosylation-site deletion proteins were 
analyzed using an indirect ELISA using BRSV-infected BT 
cells as antigen. Antibody titers were determined by the 
endpoint at which the OD410 nm given by the post-inocula-
tion plasma was higher than the pre-inoculation OD410 nm 
at the corresponding dilution, plus two times the standard 
deviation given by the pre-inoculation plasma. Also, the 
OD410 nm values given by post-inoculation plasma were 
divided by the OD410 nm values given by pre-inoculation 
plasma at the corresponding dilution to determine the sig-
nal to noise (S:N) ratio (Figure 4). Plasma collected from 
the pre-inoculation bleed and from weeks 2 and 6 did not 
have a detectable antibody response (data not shown). 
Plasma collected on day 78 from mice inoculated with the 
plasmid DNA encoding the BRSV F N-glycosylation-site 
deletion proteins had mean ELISA antibody titers that 
ranged from <1:10 to 1:56 (Table 1). Plasma from mice im-
munized IM with live BRSV was used as a positive con-
trol for the ELISA. Plasma collected from these mice had 
a mean BRSV F-specific antibody titer of 1:80. Inoculation 
with plasmid DNA encoding the WT F and Gly2/4 re-
sulted in development of significant (P < 0.05) BRSV an-
tibody titers. Mice in the WT F and Gly2/4 groups had 
mean antibody titers of 1:34 and 1:56, respectively. The 
mice inoculated with Gly4, Gly1/2/4, Gly1/2/3/4 and 
the negative control group (no treatment) did not develop 
a significant antibody response.
Figure 3. Cytoplasmic staining using an immunoperoxidase assay in COS-7 cells transiently transfected with plasmid DNA encod-
ing the WT and N-glycosylation-site deletion BRSV F proteins. (A) COS-7 cells transfected with the pcDNA 3.1 backbone, (B) COS-
7 cells transfected with DNA encoding the WT F protein. COS-7 cells transfected with DNA encoding the glycosylation-site deletion 
mutants, (C) Gly4, (D) Gly2/4, (E) Gly1/2/4 and (F) Gly1/2/3/4 mutant. Expression of the F protein was detected using MAb 8G12.
Figure 4. Anti-BRSV F IgG antibody response in BALB/c mice 
following inoculation with WT F, Gly4, Gly2/4, Gly1/2/4, 
Gly1/2/3/4, live BRSV, or no treatment. An indirect ELISA 
was used to evaluate the antibody responses to the plasmid 
DNA encoding the BRSV F proteins. Signal to noise (S:N) ra-
tios were calculated by dividing the OD410 nm given by the 
post-inoculation plasma by the OD410 nm given by the pre-inoc-
ulation plasma at the corresponding dilution.
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Plasma was also analyzed for virus neutralizing an-
tibodies against BRSV. Plasma collected on day 78 from 
mice inoculated with the plasmid DNA encoding the N-
glycosylation-site deletion proteins had mean neutraliz-
ing antibody titers that ranged from <1:10 to 1:34 (Table 
1). Of the four plasmid DNA constructs encoding N-glyco-
sylation-site deletion(s) tested, only the Gly2/4 glycosyl-
ation-site deletion construct elicited development of signif-
icant (P < 0.05) BRSV neutralizing antibodies in mice. Mice 
inoculated with WT F, Gly4, Gly1/2/4 and Gly1/2/3/4 
plasmid DNA, along with the negative control group did 
not develop significant (P < 0.05) BRSV neutralizing anti-
body responses. The positive control group, mice inocu-
lated with live virus, developed a relatively high mean vi-
rus neutralizing titer of 1:128 (Table 1).
4. Discussion
To characterize the effects of the four N-glycans of 
BRSV F protein on expression in cell culture and immu-
nogenicity in BALB/c mice, four plasmid DNAs were 
constructed, each encoding a protein with 1-4 N-gly-
cosylation-site(s) deleted: Gly4, Gly2/4, Gly1/2/4 and 
Gly1/2/3/4. The deletion mutants were constructed by 
replacing the corresponding N-glycosylation-site(s) of 
each plasmid DNA with an alanine codon, preventing N-
linked glycosylation at that site. The plasmid DNAs en-
coding the BRSV WT F and N-glycosylation-site deletion 
proteins were transfected into COS-7 cells to evaluate pro-
tein expression and were inoculated into BALB/c mice to 
evaluate their potential to induce antibody responses. To 
our knowledge, this is the first report of a study compar-
ing the effects of multiple N-glycosylation-site deletions 
of the BRSV F protein on antibody response using plas-
mid DNA.
Analyses of expression of the N-glycosylation-site de-
letion proteins in transfected COS-7 cells by an immuno-
peroxidase assay demonstrated that the protein expres-
sion among these constructs was comparable and similar 
to that of the wild-type protein. Additionally, expression 
of the plasmid DNA encoding BRSV F WT or N-glyco-
sylation-site deletion proteins in COS-7 cells was evalu-
ated by Western blot analyses. The F protein resolved as a 
68 kDa band and the F1 subunit resolved as a faint 48 kDa 
band in each cell lysate.
Antibody responses of mice inoculated with the plas-
mid DNA encoding the WT F or N-glycosylation-site de-
letion proteins were analyzed using an indirect ELISA and 
virus neutralizing antibody assay. Among the BRSV N-gly-
cosylation-site deletion protein groups, mice inoculated 
with Gly2/4 developed the highest ELISA titer and were 
the only group that developed a significant neutralizing ti-
ter. The Gly2/4 ELISA titers were greater than those elic-
ited by the WT F protein. The increase in antibody response 
in the Gly2/4 group may be attributed to the unmasking of 
an epitope or to a conformational change in the protein ex-
posing an epitope when both the second and fourth N-gly-
cans are deleted, since the single deletion, Gly4, did not in-
duce a significant antibody titer with either assay.
Removal of BRSV F N-glycans resulted in decreased 
anti-BRSV F-specific antibody responses when BALB/
c mice were inoculated with three of the four N-glyco-
sylation-site deletion constructs. Mice inoculated with 
the single (Gly4), the triple (Gly1/2/4), and the quadru-
ple (Gly1/2/3/4) N-glycosylation-site deletion constructs 
did not develop significant ELISA or virus neutralizing 
antibody titers compared to the negative control mice. 
The selective deletion of certain glycans may result in a 
change in the protein conformation, thereby changing ep-
itope presentation. Complete removal of N-glycans may 
also have inhibited the folding and transport of the pro-
tein to the cell surface, preventing exposure of the protein 
to antigen presenting cells. This could explain why mice 
inoculated with Gly1/2/3/4 did not develop measurable 
antibody responses detectable by ELISA or neutralizing 
antibody assays.
Similar observations were made with the G glycopro-
tein of HRSV [13]. The complete removal of the O- and 
N-glycans resulted in only five of 18 MAbs recognizing 
HRSV G protein, compared to the completely glycosyl-
ated protein, which was recognized by all 18 MAbs. These 
findings showed that the O- and N-glycans were crucial 
for antigenicity of the HRSV G glycoprotein [13].
Taken together, the results of this study demonstrate 
that the expression and antibody recognition of BRSV F 
protein epitopes are influenced by N-glycosylation. The 
removal of three or four N-glycosylation-sites from the 
BRSV F protein, Gly1/2/4 and Gly1/2/3/4, altered the 
protein such that antibody recognition was abolished. The 
absence of antibody response may be a result of a protein 
conformational change affecting epitope recognition or 
alteration in the transport of the protein to the cell sur-
face. Certain glycans may also mask epitopes. The greater 
mean ELISA antibody and virus neutralizing titers of 
Table 1. Anti-BRSV IgG antibody responses in BALB/c mice 
following inoculation with WT F, glycosylation-site deletion 
constructs: Gly4, Gly2/4, Gly1/2/4 and Gly1/2/3/4; live 
BRSV; or no treatment
Group       ELISA antibody titersa  Neutralizing antibody titersb
Live BRSV 1:80A 1:128A






a The mean endpoint antibody titers were determined by the last 
dilution in which the post-inoculation OD410 was higher than the pre-
inoculation OD410 plus two-times the standard deviation. Titers that 
have no common letters are significantly different (P < 0.05).
b Mean neutralizing antibody titers were determined at 100% vi-
ral inhibition by immunoperoxidase staining. Titers that have no com-
mon letters are significantly different (P < 0.05).
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Gly2/4 than those elicited by the WT F protein suggest 
unmasking of an epitope. Similar results were observed 
with the gp70 protein of Rauscher murine leukemia vi-
rus, where removal of carbohydrates from the protein im-
proved reactivity to most MAbs [22]. Similarly, the intro-
duction of a glycosylation-site at residue 63 of the 1969 
influenza virus caused the virus to be unreactive with the 
antibody specific for that residue, confirming that the ad-
dition of a glycosylation-site can mask epitopes and alter 
reactivity of antibodies with a viral protein [23].
Bovine CD4+ T cell epitopes are distributed within 
the F1 subunit (peptides 99 and 100) of the BRSV F pro-
tein [24]. Several of these regions, which were recognized 
by the CD4+ T cells from calves, are adjacent to previ-
ously identified B cell epitopes [25]. The antigenic sites 
for neutralizing MAbs to the HRSV F protein have also 
been mapped, primarily to the F1 subunit [26–28]. One 
region is near the C terminal-end of the cysteine-rich re-
gion and not far from the heptad repeat [27]. Other highly 
conserved neutralizing epitopes have been mapped to 
the amino-terminal third of the F1 subunit, near the pro-
teolytic activation site [28]. The location of the individual 
glycosylation-site on the F1 subunit could inhibit recogni-
tion of one or more antigenic sites. Also, the multiple gly-
cans located on the F2 subunit may account for so few ep-
itopes being mapped to this area.
In summary, glycosylation affects how the BRSV F pro-
tein elicits a humoral immune response. The Gly2/4 de-
letion protein elicited the greatest mean ELISA antibody 
titer of the glycosylation-site deletion proteins tested, 
which was greater than the mean titer elicited by the fully 
glycosylated WT F. It was also the only glycosylation-site 
deletion protein that elicited a significant virus neutraliz-
ing antibody titer. Gly4, Gly1/2/4 and Gly1/2/3/4 did 
not elicit a significant ELISA or virus neutralizing anti-
body response. Continued studies using BRSV F glycosyl-
ation-site deletion proteins in the natural host to charac-
terize the effects of glycosylation on immunogenicity may 
lead to a new approach for generation of BRSV vaccines 
[29].
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